Subscribe to Search results

Alpha issued a press release warning of a real risk of AIDS from taking Factor 8 concentrates.

Published on:

Dr John Petricciani of the Food and Drug Administration sent a letter to all Licensed Manufacturers of Plasma Derivatives recommending excluding high risk plasma from blood products.

Published on:

The US Blood Products Advisory Committee discussed product recall and concluded it should be decided on a case-by-case basis.

Published on:

Notes on Transfusion by Ministry of Health warned of risks of transfusion.

Published on:

A parent of a Treloar's student provided consent for their son to take part in a DDAVP trial but asked for further information about this "other substance".

Published on:

In 1976 over 600,000 units of cryoprecipitate, just over 150,000 units of NHS Factor 8 and over 1,000,000 units of three different commercial concentrates were used at Treloar's.

Published on:

In 1977 cryoprecipitate and NHS factor concentrates were both used at Treloar's, as well as four commercial products.

Published on:

Blood Concentrate products were most probably first used at Treloar's after March 1969.

Published on:

In a letter to Dr Maycock, Dr Rainsford stated that the Treloar's students had not been adequately treated with AHG before he had arrived at the school.

Published on:

Dr Iain Frew, the home clinician of a Treloar's student, wrote to Dr Aronstam regarding the higher doses of cryoprecipitate provided by Treloar's.

Published on:

Dr Aronstam stated in a letter that the use of prophylaxis was a routine at Treloar's "in many clinical situations" and described the programme as "admittedly enthusiastic".

Published on:

Stephen Nicholls recollected that prophylaxis treatment was really pushed at Treloar's.

Published on:

Following two trials, Dr Aronstam recognised the potential where prophylaxis reduced the frequency of bleeding episodes and the potential danger of hyper-transfusion with blood products.

Published on:

Dr Swinburne (Leeds Haemophilia Centre) suggested that it was wise that the patient be treated with one product and Hemofil was recommended.

Published on:

Dr Aronstam stated that Treloar's patients had already had five different types of concentrates and he prefered not to "confine [himself] to a single Concentrate."

Published on:

Dr Rizza suggested that some of the Treloar's pupils, if possible, should receive NHS material.

Published on:

Dr Aronstam wrote that prophylaxis was "much more effective given on alternate days than twice weekly".

Published on:

Dr Aronstam stated that he had not seen hard data to prove the benefits of lower doses of Factor 8.

Published on:

Dr Aronstam stated "we only give prophylaxis in short courses here and only when a particular joint is being threatened. I am afraid we do not have the resources to give any of our 55 severe haemophiliac boys a long course of prophylaxis just because of bleeding frequency".

Published on:

The chief executive of Speywood stated that Dr Aronstam's "first requirement is convenience of administration" when deciding what treatment to provide to Treloar's students.

Published on: